1. Volume 151, Issue 5, Pages 1069-1080 (May 2017)
Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection 
Ivan F.N. Hung, MD, Kelvin K.W. To, MD, Jasper F.W. Chan, MBBS, Vincent C.C. Cheng, MD, Kevin S.H. Liu, MBChB, Anthony Tam, MBBS, Tuen-Ching Chan, MD, Anna Jinxia Zhang, PhD, Patrick Li, MSc, Tin-Lun Wong, BSc, Ricky Zhang, MSc, Michael K.S. Cheung, MBBS, William Leung, MBBS, Johnson Y.N. Lau, MD, Manson Fok, MD, Honglin Chen, PhD, Kwok-Hung Chan, PhD, Kwok-Yung Yuen, MD 
CHEST 
Volume 151, Issue 5, Pages (May 2017)
DOI: /j.chest
Copyright © 2016 American College of Chest Physicians Terms and Conditions

2. Figure 1
Recruitment flowchart of the 217 subjects. CrCl = creatinine clearance; CXR = chest radiograph.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 American College of Chest Physicians Terms and Conditions

3. Figure 2
The 30-day survival in patients treated with the clarithromycin-naproxen-oseltamivir combination and with oseltamivir alone.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 American College of Chest Physicians Terms and Conditions

4. Figure 3
Profile of virus titer after treatment. Error bars represent SEM. Significant P < .05 shown in bold.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 American College of Chest Physicians Terms and Conditions

5. Figure 4
Profile of pneumonia severity index after treatment. Error bars represent SEM. Significant P < .05 shown in bold. PSI = pneumonia severity index.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 American College of Chest Physicians Terms and Conditions

6. Figure 5
Percentage of patients with ≥ 5% NIRV quasispecies detected. Significant P < .05 shown in bold. NIRV = neuraminidase-inhibitor-resistant A(H3N2) virus.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 American College of Chest Physicians Terms and Conditions